Biotias Newest Software for SARS-CoV-2 Genetic Surveillance Sees Rapid Adoption By Researchers Seeking Deeper Insights
Summary
Biotias COVID-DX software has been optimized for researchers sequencing COVID-19 clinical specimens and wastewater samples using the popular ARTIC, amplicon-based approach, as well as a hybridization-capture based method. "As SARS-CoV-2 continues to evolve and sub-lineages of the Delta variant emerge, ongoing sequencing surveillance and advanced tools to aid researchers and clinicians in the interpretation of their results is essential. "Our advanced technology supports NGS-based surveillance by implementing insightful variant and lineage reporting in agreement with the CDC classifications," said Niamh B. OHara, Ph.D., CEO and co-founder of Biotia. Operating out of their Brooklyn-based CLIA lab, Biotia offers a complete solution for COVID-19 testing including rapid diagnostics, sequencing services, and software analytics. Biotia, a spinout company of Jacobs Technion-Cornell Institute at Cornell Tech has a New York State CLIA lab for COVID-19 testing affiliated with SUNY Downstate Health Sciences University.